Unknown

Dataset Information

0

De novo variants are a common cause of genetic hearing loss.


ABSTRACT:

Purpose

De novo variants (DNVs) are a well-recognized cause of genetic disorders. The contribution of DNVs to hearing loss (HL) is poorly characterized. We aimed to evaluate the rate of DNVs in HL-associated genes and assess their contribution to HL.

Methods

Targeted genomic enrichment and massively parallel sequencing were used for molecular testing of all exons and flanking intronic sequences of known HL-associated genes, with no exclusions on the basis of type of HL or clinical features. Segregation analysis was performed, and previous reports of DNVs in PubMed and ClinVar were reviewed to characterize the rate, distribution, and spectrum of DNVs in HL.

Results

DNVs were detected in 10% (24/238) of trios for whom segregation analysis was performed. Overall, DNVs were causative in at least ∼1% of probands for whom a genetic diagnosis was resolved, with marked variability based on inheritance mode and phenotype. DNVs of MITF were most common (21% of DNVs), followed by GATA3 (13%), STRC (13%), and ACTG1 (8%). Review of reported DNVs revealed gene-specific variability in contribution of DNV to the mutational spectrum of HL-associated genes.

Conclusion

DNVs are a relatively common cause of genetic HL and must be considered in all cases of sporadic HL.

SUBMITTER: Klimara MJ 

PROVIDER: S-EPMC9729384 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

De novo variants are a common cause of genetic hearing loss.

Klimara Miles J MJ   Nishimura Carla C   Wang Donghong D   Kolbe Diana L DL   Schaefer Amanda M AM   Walls William D WD   Frees Kathy L KL   Smith Richard J H RJH   Azaiez Hela H  

Genetics in medicine : official journal of the American College of Medical Genetics 20221004 12


<h4>Purpose</h4>De novo variants (DNVs) are a well-recognized cause of genetic disorders. The contribution of DNVs to hearing loss (HL) is poorly characterized. We aimed to evaluate the rate of DNVs in HL-associated genes and assess their contribution to HL.<h4>Methods</h4>Targeted genomic enrichment and massively parallel sequencing were used for molecular testing of all exons and flanking intronic sequences of known HL-associated genes, with no exclusions on the basis of type of HL or clinical  ...[more]

Similar Datasets

| S-EPMC7940174 | biostudies-literature
| S-EPMC4067994 | biostudies-literature
| S-EPMC9166542 | biostudies-literature
| S-EPMC7990330 | biostudies-literature
| S-EPMC7434732 | biostudies-literature
| S-EPMC6612514 | biostudies-literature
| S-EPMC6514080 | biostudies-literature
| S-EPMC8422347 | biostudies-literature
| S-EPMC6871531 | biostudies-literature
| S-EPMC7507023 | biostudies-literature